PL3765055T3 - Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych - Google Patents
Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnychInfo
- Publication number
- PL3765055T3 PL3765055T3 PL19710418.5T PL19710418T PL3765055T3 PL 3765055 T3 PL3765055 T3 PL 3765055T3 PL 19710418 T PL19710418 T PL 19710418T PL 3765055 T3 PL3765055 T3 PL 3765055T3
- Authority
- PL
- Poland
- Prior art keywords
- bacterial
- treatment
- infectious diseases
- binding peptides
- inflammatory processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382164 | 2018-03-13 | ||
| PCT/EP2019/056315 WO2019175261A1 (en) | 2018-03-13 | 2019-03-13 | Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3765055T3 true PL3765055T3 (pl) | 2023-11-27 |
Family
ID=61768231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19710418.5T PL3765055T3 (pl) | 2018-03-13 | 2019-03-13 | Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11660326B2 (pl) |
| EP (1) | EP3765055B9 (pl) |
| JP (1) | JP7792115B2 (pl) |
| AU (1) | AU2019233613B2 (pl) |
| CA (1) | CA3133008A1 (pl) |
| ES (1) | ES2953362T3 (pl) |
| HR (1) | HRP20230984T1 (pl) |
| HU (1) | HUE062829T2 (pl) |
| PL (1) | PL3765055T3 (pl) |
| RS (1) | RS64455B1 (pl) |
| WO (1) | WO2019175261A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017360043A1 (en) * | 2016-11-18 | 2019-06-20 | Hospital Clinic De Barcelona | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
| EP4272837A3 (en) | 2019-08-02 | 2024-02-28 | Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer | Car t-cells against bcma for the treatment of multiple myeloma |
| US10881781B1 (en) | 2020-04-29 | 2021-01-05 | Orth Consulting, Llc | Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530838A (ja) * | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| WO2008119851A1 (es) | 2007-03-28 | 2008-10-09 | Universidad De Barcelona | Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
| JP2014516046A (ja) * | 2011-05-26 | 2014-07-07 | フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ | がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質cd5又はcd6 |
| DK3221313T3 (en) | 2014-11-17 | 2019-04-08 | Entasis Therapeutics Ltd | COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA |
| WO2018025052A1 (en) | 2016-08-04 | 2018-02-08 | Oxford University Innovation Limited | Chimeric antigen receptors |
| AU2017360043A1 (en) | 2016-11-18 | 2019-06-20 | Hospital Clinic De Barcelona | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
-
2019
- 2019-03-13 EP EP19710418.5A patent/EP3765055B9/en active Active
- 2019-03-13 HR HRP20230984TT patent/HRP20230984T1/hr unknown
- 2019-03-13 PL PL19710418.5T patent/PL3765055T3/pl unknown
- 2019-03-13 ES ES19710418T patent/ES2953362T3/es active Active
- 2019-03-13 US US16/980,275 patent/US11660326B2/en active Active
- 2019-03-13 JP JP2020572616A patent/JP7792115B2/ja active Active
- 2019-03-13 RS RS20230680A patent/RS64455B1/sr unknown
- 2019-03-13 WO PCT/EP2019/056315 patent/WO2019175261A1/en not_active Ceased
- 2019-03-13 HU HUE19710418A patent/HUE062829T2/hu unknown
- 2019-03-13 AU AU2019233613A patent/AU2019233613B2/en active Active
- 2019-03-13 CA CA3133008A patent/CA3133008A1/en active Pending
-
2023
- 2023-04-19 US US18/303,441 patent/US20230381266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019233613A1 (en) | 2020-10-29 |
| HUE062829T2 (hu) | 2023-12-28 |
| RS64455B1 (sr) | 2023-09-29 |
| JP7792115B2 (ja) | 2025-12-25 |
| ES2953362T3 (es) | 2023-11-10 |
| EP3765055B9 (en) | 2023-09-27 |
| EP3765055B1 (en) | 2023-06-07 |
| EP3765055A1 (en) | 2021-01-20 |
| HRP20230984T1 (hr) | 2023-12-08 |
| US20210023162A1 (en) | 2021-01-28 |
| AU2019233613B2 (en) | 2025-02-13 |
| CA3133008A1 (en) | 2019-09-19 |
| EP3765055C0 (en) | 2023-06-07 |
| US11660326B2 (en) | 2023-05-30 |
| JP2021518426A (ja) | 2021-08-02 |
| US20230381266A1 (en) | 2023-11-30 |
| WO2019175261A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285269A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| IL280563A (en) | Anti-btn3a antibodies and their use in treating cancer or infectious disorders | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| IL263174A (en) | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| EP3359171C0 (en) | Use of akkermansia muciniphila for treating inflammatory conditions | |
| EP3538548A4 (en) | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| PL3774897T3 (pl) | Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi | |
| MA49413A (fr) | Traitement de gaz acide | |
| IL273705B (en) | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| EP3713955A4 (en) | ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| IL264070A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| IL291192A (en) | Compositions and methods of treating lupus nephritis | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| PL3765055T3 (pl) | Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych | |
| IL285268A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL283039A (en) | Immunogenic compositions for treatment of hepatitis b | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
| EP4081250A4 (en) | ALLERGY TREATMENT |